Literature DB >> 26550313

Predictive and prognostic molecular markers for cholangiocarcinoma in Han Chinese population.

Lingqin Meng1, Zhong Tian1, Yong Wang1, Yuan Liu1, Jingang Liu1.   

Abstract

Cholangiocarcinoma (CCA) is the most common malignant heterogeneous polygenetic carcinoma with a high incidence in Asia. Most patients would die within 1 year after diagnosis and the 5 year survival rate is less than 10-20% worldwide. Single nucleotide polymorphisms (SNPs) in genes regulate telomere maintenance, mitosis, and inflammation, and may help predict individual susceptibility to certain drugs, environmental factor, and risks to particular diseases. The gene-gene interaction and the regulation of SNPs have not been assessed extensively in CCA. According to our previous study, the GRB2-associated-binding protein (Gab1) gene rs3805246 (X(2) =5.015, P=0.025, OR=0.531, 95% CI 0.304-0.928) and epidermal growth factor receptor (EGFR) gene rs2007000 (X(2) =7.934, P=0.005, OR=2.148, 95% CI 1.255-3.675) presented significant difference between CCA patients and controls. This study conducted a population-based analysis using 225 CCA cases (153 biliary tract cancer patients and 72 gall bladder cancer patients) to assess the association between SNPs and progression of CCA patients, including the overall survival and the prognosis analysis. Results showed that an increased susceptibility of BTC was significantly associated with SNP loci distribution frequency in EGFR rs2107000 (X(2) =7.934, P=0.005, OR=2.148, 95% CI 1.255-3.675). Furthermore, multivariate factor regression analysis represented cholelithiasis medical history of BTC patients can be an effective evaluation criteria of BTC susceptibility in early stage. This study also assessed the relationship between these genotypic polymorphisms and clinicopathologic data, including tumor differentiation stage and overall survival. This is the first study identifying that EGFR polymorphisms are associated with BTC and EGFR rs2017000 polymorphisms may be an important survival predictor in BTC patients.

Entities:  

Keywords:  Cholangiocarcinoma; SNPs; molecular marker

Year:  2015        PMID: 26550313      PMCID: PMC4612998     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  39 in total

1.  Foreword. Target therapy for cancer: anti-cancer drugs targeting growth-factor signaling molecules.

Authors:  Fumiaki Ito
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

Review 2.  Using high-throughput SNP technologies to study cancer.

Authors:  L J Engle; C L Simpson; J E Landers
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

Review 3.  Genetic profiling of intrahepatic cholangiocarcinoma.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Curr Opin Gastroenterol       Date:  2012-05       Impact factor: 3.287

4.  The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer.

Authors:  Ulrich H Frey; Andreas Eisenhardt; Gerd Lümmen; Herbert Rübben; Karl-Heinz Jöckel; Kurt W Schmid; Winfried Siffert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-04       Impact factor: 4.254

5.  GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer.

Authors:  Ulrich H Frey; Hakan Alakus; Jeremias Wohlschlaeger; Klaus J Schmitz; Günther Winde; Hans G van Calker; Karl-Heinz Jöckel; Winfried Siffert; Kurt W Schmid
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

6.  Cancer incidence trends in urban Shanghai, 1972-1989.

Authors:  F Jin; S S Devesa; W Zheng; W J Blot; J F Fraumeni; Y T Gao
Journal:  Int J Cancer       Date:  1993-03-12       Impact factor: 7.396

7.  Infection with the carcinogenic liver fluke Opisthorchis viverrini modifies intestinal and biliary microbiome.

Authors:  Jordan L Plieskatt; Raksawan Deenonpoe; Jason P Mulvenna; Lutz Krause; Banchob Sripa; Jeffrey M Bethony; Paul J Brindley
Journal:  FASEB J       Date:  2013-08-07       Impact factor: 5.191

Review 8.  Imaging bile duct tumors: pathologic concepts, classification, and early tumor detection.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Abdom Imaging       Date:  2013-12

9.  KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Authors:  F Loupakis; A Ruzzo; C Cremolini; B Vincenzi; L Salvatore; D Santini; G Masi; I Stasi; E Canestrari; E Rulli; I Floriani; K Bencardino; N Galluccio; V Catalano; G Tonini; M Magnani; G Fontanini; F Basolo; A Falcone; F Graziano
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

10.  Genome-wide association study identifies novel breast cancer susceptibility loci.

Authors:  Douglas F Easton; Karen A Pooley; Alison M Dunning; Paul D P Pharoah; Deborah Thompson; Dennis G Ballinger; Jeffery P Struewing; Jonathan Morrison; Helen Field; Robert Luben; Nicholas Wareham; Shahana Ahmed; Catherine S Healey; Richard Bowman; Kerstin B Meyer; Christopher A Haiman; Laurence K Kolonel; Brian E Henderson; Loic Le Marchand; Paul Brennan; Suleeporn Sangrajrang; Valerie Gaborieau; Fabrice Odefrey; Chen-Yang Shen; Pei-Ei Wu; Hui-Chun Wang; Diana Eccles; D Gareth Evans; Julian Peto; Olivia Fletcher; Nichola Johnson; Sheila Seal; Michael R Stratton; Nazneen Rahman; Georgia Chenevix-Trench; Stig E Bojesen; Børge G Nordestgaard; Christen K Axelsson; Montserrat Garcia-Closas; Louise Brinton; Stephen Chanock; Jolanta Lissowska; Beata Peplonska; Heli Nevanlinna; Rainer Fagerholm; Hannaleena Eerola; Daehee Kang; Keun-Young Yoo; Dong-Young Noh; Sei-Hyun Ahn; David J Hunter; Susan E Hankinson; David G Cox; Per Hall; Sara Wedren; Jianjun Liu; Yen-Ling Low; Natalia Bogdanova; Peter Schürmann; Thilo Dörk; Rob A E M Tollenaar; Catharina E Jacobi; Peter Devilee; Jan G M Klijn; Alice J Sigurdson; Michele M Doody; Bruce H Alexander; Jinghui Zhang; Angela Cox; Ian W Brock; Gordon MacPherson; Malcolm W R Reed; Fergus J Couch; Ellen L Goode; Janet E Olson; Hanne Meijers-Heijboer; Ans van den Ouweland; André Uitterlinden; Fernando Rivadeneira; Roger L Milne; Gloria Ribas; Anna Gonzalez-Neira; Javier Benitez; John L Hopper; Margaret McCredie; Melissa Southey; Graham G Giles; Chris Schroen; Christina Justenhoven; Hiltrud Brauch; Ute Hamann; Yon-Dschun Ko; Amanda B Spurdle; Jonathan Beesley; Xiaoqing Chen; Arto Mannermaa; Veli-Matti Kosma; Vesa Kataja; Jaana Hartikainen; Nicholas E Day; David R Cox; Bruce A J Ponder
Journal:  Nature       Date:  2007-06-28       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.